Cytokinetics Inc.
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Open CYTK dashboard ↗Pluri Inc. Common Stock
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. The company's product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. It also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. The company operates in the field of regenerative medicine, food tech, immunotherapy, CDMO, and AgTech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Open PLUR dashboard ↗